Tristel Share Discussion Threads

[eeza] 08/7/2016 16:12

"Iff there is any news they will be holding it back for the "investor day".


They'll have their collars felt for creating a false market in that case. Price-sensitive news has to be released immediately.

[apad] 08/7/2016 14:31

It's all about the US. If you succeed there it's not like anywhere else.
The CEO (say it quietly in case Piedro is listening) says that selling into the NHS is the worst that there ever was (Talking Heads).
Whatever happens to the share price under tiddly little PI buying and selling is as of nothing. Iff there is any news they will be holding it back for the "investor day".
It's exciting if nothing else :-)
apad

[bolador] 08/7/2016 12:40

Piedro,

Thanks for the comment on imported materials.I was hoping, now that the UK market penetration by Tristel in the NHS is almost complete, that the drive would be for overseas sales. Most important for the future of the company and lower sterling would help on balance. But we will see..

[apad] 08/7/2016 11:58

Added a few at 90.8p
FWIW
apad

[piedro] 08/7/2016 11:48

At least the BoD hold +30% of the shares.
If they are are at a dead end then the usual t/o deal is that they sell out cheap and the executives get jobs in the new company.

{edited}
- I've been stung 3 times like that ... HMY, VDN and AND

[spud] 08/7/2016 11:31

Lets not forget that a low £ allied to depressed market caps of some profit making companies makes for a very tastey t/o proposition.

The Yanks & Chinese could soon be eyeing up some of our businesses imo.

spud

[piedro] 08/7/2016 11:14

BREXIT!!

Costs of Materials of £4.673m for 2015
How much of that is imported or made from imports?

The USA regulatory costs will be higher

I agree with you re: the products - there should be no problem with the sales

[bolador] 08/7/2016 10:16

Whats happened here, did not look at the share price for a day or two and bang ? Not affected by BREXIT except sterling devaluation which must help.
Most likely nervous sellers into unwilling market and with trading update due none of the directors can buy right now.

Still any shocks at the trading update now hopefully pre-accidentised (made up word but enjoyable) at the current share price

As an aside I would have thought the products were in sustained high demand with the advent of general antibiotic resistance we are back to keeping hospitals spotless and disinfected.

[piedro] 06/7/2016 14:16

Fortune favours the brave

Well done Spud.

A fertile imagination can project all sorts of things able go wrong.
They've done alright so far, at worst you could pick up some more
around 80p.
As mentioned many times, I'd feel happier with a new Chairman
AIMO
and GL

P.

[spud] 06/7/2016 12:38

Providing this drop is market sentiment & not bad news around the corner, I've continued to take advantage to the tune of an additional 15k over the past 7 days.

If it's the former, then I fully expect to be quids in following the trading update on the 21st.

spud

[piedro] 01/7/2016 00:51

First impression ...

"What a mess!"

... AIMO

[piedro] 30/6/2016 23:55

Just got my system back up

- will have a look
+ redo header ... sometime

[apad] 30/6/2016 23:24

Impressive.
apad

[murray80] 30/6/2016 21:49

Look a Tristel's new website

[glaws2] 20/6/2016 12:18

The specific answer (above) was for verdict in summer 2017. The submission date I have (end of 2016) was directly from Paul Swinney at the meeting I was in. I'm not being deliberately pedantic here but if you are expecting a big announcement on submission at the July shareholder event then I believe you are going to be disappointed.

I could of course be pleasantly suprised.

[apad] 20/6/2016 11:03

Paton puts it well as a series of questions:

Question not asked.

4a) FDA approval: Can management confirm that FDA submission is still on track for June 2016 and an outcome is still on track for June 2017?

* Still on track for a verdict in summer 2017.

* Registration costs have come to £60k in FY 2015 and £40k in H1 2016, and will come to £80k in H2 2016.

* Costs of full submission will then add an extra £400-500k to the bill.

* If approval is won, no material costs of USA operation. There will be no US subsidiary or presence.

* Instead TSTL will partner with instrument suppliers. Example cited of the two main ophthalmology instrument manufacturers, with whom TSTL already works with in overseas territories. US plan is to use the sales infrastructure of these instrument manufacture to sell products etc, as customers ask “how do we disinfect your instruments?”

* US approach described as “relatively risk-averse”.

4b) FDA approval: Can management outline the possible reasons why FDA could REJECT its submission and the likelihood of such a verdict.

* “Incomplete or unsatisfactory data”

* FDA has never approved a high-level foam-formatted disinfectant before, nor has it approved a high-level chlorine-dioxide disinfectant before.

* But the FDA has approved a chlorine disinfectant (from UK firm Sterelox) and a foam-y type (hydrogen peroxide nebuliser) disinfectant (from Australia) before now. So there is some hope that all will be well with TSTL’s submission.

[glaws2] 20/6/2016 10:45

APAD - your date is wrong - they expect to submit their dossier/application by the end of 2016 (this was stated in their post results meetings in Feb). At that time they were compiling a list of questions for the FDA and hoped to arrange a meeting so that they could firmly establish exactly what the dossier needed to contain in support of their application.

[jaf111] 20/6/2016 09:13

Not so sure about Trading Update on 30 June..... From last RNS

"The Company will also provide the market with an update on trading for the year ending 30 June 2016 on Thursday 21 July 2016."

[apad] 20/6/2016 08:45

ps

Trading update on 30 June. Not a coincidence re FDA

"by June" means end of May to me!

Open day 12 noon 21st July. Time to cope with flac/bouquets.

[apad] 20/6/2016 08:39

The company hopes to submit an application to the FDA by June 2016, to launch two Clo2 foam based products
Summer 2017 FDA approval. 2016 submission.

This is why the share price is languishing.

apad

[spud] 13/6/2016 14:30

Taken some more @ 116p.

spud

[spud] 09/6/2016 11:05

Poised to bounce again imo - Can't buy any meaningful volume online.

spud

[rimmy2000] 03/6/2016 20:59

i have requested to attend the summer event in Snailwell, Cambs. I think this is poised to move upwards next week based on chart action this week.